News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Australian stem cell and regenerative medicine company Cynata Therapeutics is now set to scale up manufacturing of its mesenchymal stem cells (MSCs) for therapeutic use.
Cobra Biologics will work with UK academics to fine tune E.coli for protein production in a Government backed project announced this week.
Celltrion says the two-brand strategy for its Remicade biosimilar will help it cater for local needs and cultural differences.